Objectives Evidence supports tocilizumab (TCZ) benefit and safety in adult patients with
severe COVID-19. However, its effectiveness in critically ill older adult patients remains …

Importance Pneumonia due to COVID-19 can lead to respiratory failure and death due to the
development of the acute respiratory distress syndrome. Tocilizumab, a monoclonal …

Objective Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …

Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …

Introduction The aim of this study was to determine the efficacy of early tocilizumab treatment
for hospitalized patients with COVID-19 disease. Methods Open-label randomized phase II …

Materials and methods Online databases (PubMed and Cochrane) were searched until
June 29, 2020, for original articles investigating the immunological response in COVID-19 …

Background: Accumulating evidence points to an overactive immune response in Covid-19
disease and potential clinical benefit of the interleukin-6 inhibitor tocilizumab. We assessed …

Abstract Background Coronavirus disease 2019 (COVID-19) has killed over 2.5 million
people worldwide, but effective care and therapy have yet to be discovered. We conducted …

Objectives The purpose of this study is to evaluate clinical outcomes in patients with critical
COVID-19 pneumonia requiring invasive mechanical ventilation who were treated with …

Background Interleukin-6 inhibitors showed promising results in observational trials of
patients with coronavirus disease 2019 (COVID-19). Aim To evaluate whether interleukin-6 …